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Abstract: Hypertension is a typical example of long-term disease
posing formidable challenges to health care. One goal of antihyperten-
sive therapy is to achieve optimal blood pressure (BP) control and
reduce co-occurring chronic conditions (multimorbidity). This study
aimed to assess the influence of multimorbidity on medication adher-
ence, and to explore the association between poor BP control and
multimorbidity, with implications for hypertension management.
A cross-sectional design with multistage sampling was adopted to
recruit Chinese hypertensive patients attending general out-patient clinics
from 3 geographic regions in Hong Kong. A modified systemic sampling
methodology with 1 patient as a sampling unit was used to recruit
consecutive samples in each general out-patient clinic. Data were col-
lected by face-to-face interviews using a standardized protocol. Poor BP
control was defined as having systolic BP/diastolic BP 130/80mm Hg
for thosewith diabetes or chronic kidney disease; and140/90mmHg forQ.L. Liu, MPhil, Lee, MPH,
, FRCP, and Ruo Ling Chen, PhD, FRSM
long-term conditions. Binary logistic regression analysis was conducted
with medication adherence and multimorbidity as outcome variables,
respectively, after controlling for effects of patient-level covariates.
The prevalence of multimorbidity was 47.4% (95% confidence
interval [CI] 45.4%–49.4%) among a total of 2445 hypertensive
patients. The proportion of subjects having 0, 1, and 2 additional
long-term conditions was 52.6%, 29.1%, and 18.3%, respectively. The
overall rate of poor adherence to medication was 46.6%, whereas the
rate of suboptimal BP control was 48.7%. Albeit the influence of
multimorbidity on medication adherence was not found to be statisti-
cally significant, patients with poorly controlled BP were more likely
to have multimorbidity (adjusted odds ratio 2.07, 95% CI 1.70–2.53,
P< 0.001). Diabetes was the most prevalent concomitant long-term
condition among hypertensive patients with poor BP control (38.6%,
95% CI 35.8–41.4 vs 19.7%, 95% CI 17.5–21.9 for patients with good
BP control, P< 0.001).
Multimorbidity was common among hypertensive patients, and was
associated with poor BP control. Subjects with coexisting diabetes,
heart disease, or chronic kidney disorder should receive more clinical
attention to achieve better clinical outcomes.
(Medicine 95(20):e3572)
Abbreviations: BP = blood pressure, MMAS = Morisky
Medication Adherence Scale.
INTRODUCTION
H ypertension is one of the most prevalent long-term diseasesseen in primary care settings in many countries. High
blood pressure (BP) is often asymptomatic; yet it accounts
for approximately half of the incidence of stroke and ischemic
heart diseases worldwide, posing a formidable challenge to
health care.1,2 There is a tendency for risk factor clustering
among hypertensive patients.3,4 More importantly, the number
needed to treat to prevent a cardiovascular event or a death from
all causes is significantly lower among hypertensive patients
with added cardiovascular diseases or other complications,
when compared with hypertension alone.5 Multimorbidity,
often defined as the coexistence of more than 1 long-term
condition within 1 subject,6 represents a critical healthcare
issue internationally.6–9 A study with a large, nationally repre-
sentative sample in Scotland, UK, showed that there were more
people living with multimorbidity than a single disease alone.10
The co-existing long-term conditions have many challenges,11
including higher treatment burden7and more complex health-at in the United Kingdom, the public
ng Kong provides primary care services
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that are heavily subsidised by the government. The majority of
chronic disease care is delivered by primary care physicians
working at the general out-patient clinics (GOPCs).13 The load
of Chinese adult patients with hypertension is increasing.14 A
Hong Kong Reference Framework for Hypertension Care for
Adults in Primary Care Settings was firstly released in 2010 to
enhance the disease management of hypertension in primary
care.15 It consisted of a series of different modules addressing
various components of disease management including preven-
tion, early identification, clinical care, and patient empower-
ment. The ultimate goal of hypertension management is to
obtain maximal reduction in cardiovascular morbidity and
mortality through BP-lowering strategy. Antihypertensive
medication therapy plays an important role to achieve optimal
BP control and reduce co-occurring chronic conditions. The
benefits from patients’ adherence to antihypertensive therapies
could be reflected by substantial reductions in the incidence of
stroke (by 35%–40%), myocardial infarction (by 20%–25%),
and heart failure (by >50%).16
However, the rates of BP control remain unsatisfactory
across the globe.17,18 Only 1 or 2 out of 10 patients with
hypertension achieved optimal BP control worldwide.19 Of
patients receiving anti-hypertensive drug therapies, many
remain above recommended BP targets.20 Global statics
showed that developed countries had slightly higher BP
control rate in all hypertensive patients (10.8% vs 9.8% for
males; and 17.3% vs 16.2% for females) when compared with
developing countries; yet there were no significant differ-
ences.19 Insufficient optimal BP control remains a major
challenge in the community in both developed and developing
countries, particularly for healthcare settings heavily bur-
dened with chronic disease care. Nevertheless, there is a
paucity of data investigating the adherence in medicine taking
in the presence of accompanying chronic conditions, and few
studies have examined how BP control is linked with
additional disorders among hypertensive individuals. The
main objectives of our study were therefore to assess the
influence of multimorbidity on medication adherence, and to
Li et alexplore the association between suboptimal BP control and
multimorbidity among hypertensive patients seen in primary
care settings.
METHODS
Settings and Sampling Method
The GOPCs in Hong Kong are the primary care provider
for all citizens in the public healthcare sector, operated under the
Hospital Authority in Hong Kong. GOPCs are organized into 7
hospital clusters based on 3 geographic locations—the Hong
Kong Island, Kowloon, and the New Territories. The healthcare
services provided in GOPCs include management of both
chronic conditions and episodic illnesses, covering the entire
Hong Kong population. Hypertension is one of the most long-
term conditions seen in the GOPCs.13 A multistage sampling
design was adopted in this study. In the first stage, 1 cluster was
randomly selected in each of the 3 geographic regions (Hong
Kong West cluster which operates 7 GOPCs in Hong Kong
Island; Kowloon Central Cluster which operates 6 GOPCs in
Kowloon; and New Territories East Cluster which operates 7
GOPCs in the New Territories). In the second stage, 1 GOPC
was randomly selected in each cluster, respectively. Each GOPC
clinic is managed by approximately 10 to 15 family physicians
with qualified clinical training. There are around 300 to 500
2 | www.md-journal.compatient visits daily in each clinic, excluding evening clinic
sessions. In the third stage, a modified systemic random
sampling methodology with 1 patient as a sampling unit was
used to recruit consecutive samples in each GOPC. We divided
the estimated number of hypertensive patients visiting the
practice on the day of recruitment (Ntotal) by the number of
hypertensive patients planned to recruit on that day (Npro-
posed), which gave a number X. An integer was then randomly
selected from 1 to X, say 3, and the 1st, 4th, 7th, 10th, . . .,
consecutive patients were invited to participate in the study. The
total number of patients recruited in each clinic was determined
by the population proportion in the respective region.
Outcome Variables and Covariates
Optimal BP control was defined as having a clinical
measurement of systolic BP (SBP) <140mm Hg and diastolic
BP (DBP) <90mm Hg, whereas for patients with diabetes
mellitus or chronic kidney diseases, the corresponding threshold
was SBP <130mm Hg and DBP <80mm Hg.15,21–24 Medi-
cation adherence was assessed by the 8-item Morisky Medi-
cation Adherence Scale (MMAS-8), which is a commonly used,
validated, and self-reported adherence measure of cardiovas-
cular mediations.25 The MMAS-8 total score was calculated by
summing the values from all 8 items, with reverse coding when
necessary. A cut-off score of 6 (out of a full range of 8) was used
to identify optimal medication adherence (MMAS-8 score
>6).26–28
A simple unweighted enumeration of the number of
chronic diseases29,30 was adopted to measure the combinations
of coexisting long-term conditions. International references
were made to a UK definition10 and our previous study con-
ducted in China.8 To take into account the local healthcare
context, long-term conditions that were mostly self-reported by
patients in a recent territory-wide survey in Hong Kong31 were
also included after a panel review among a family physician, 2
public health professionals, and an epidemiologist. All con-
ditions were physician-diagnosed, and were either prevalent
among the general patients (eg, inflammatory connective tissue
disorders), or concomitant comorbidities related to hyperten-
sion (eg, diabetes, lipid disorders, heart disease, cerebrovascular
disease, nephritis, and chronic kidney disorder). Multimorbidity
was defined as the presence of 1 or more long-term condition in
addition to hypertension.32
Sample Size Estimation
The Kish L formula33: N¼ ([Za/2]2P [1P]
[1þm])/(d2), with Za/2¼ 1.96, a¼ 0.05, was used to explore
the prevalence of coexisting long-term conditions (multimor-
bidity) among hypertensive patients. We estimated the preva-
lence of additional chronic conditions among hypertensive
patients attending primary care settings as P¼ 50%. The allow-
able error was set at 0.03 and the allowable missing data were
set at 0.1. The above formula gave a minimum sample size of
1986 in total, which was also deemed adequate for logistic
regression analysis based on the rule of thumb, suggesting a
minimum of 10 events per predictor variable for logistic
models.34
Subject and Interviewer Recruitment
When attending GOPCs, all patients need to register at the
Medicine  Volume 95, Number 20, May 2016reception. After registration, patients usually queue up at the
BP-measuring station in a separate area inside the waiting hall,
before consulting the physician. All patients attending on the
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day of study recruitment were instructed to have their BP
measured. We followed the inclusion criteria to invite eligible
patients to participate in the study: Chinese patients aged 18
years or above; with physician-diagnosed hypertension includ-
ing both essential and secondary hypertension; already on
antihypertensive medication regime for at least 4 weeks before
the study; mentally capable to communicate in Chinese; and
willing to give written informed consent to participate in the
study. Patients with newly diagnosed hypertension on the day of
the recruitment were excluded as their medication adherence
afterwards was unable to measure in this cross-sectional study.
Eligible subjects were then interviewed by trained interviewers
in a private consultation session during their clinic visits. We
recruited interviewers from university medical students and
conducted 4 training sessions (delivered by KQLL and HHXW)
to standardize interview processes and minimize inter-
interviewer variances.
A total of 2700 consecutive adult patients taking antihy-
pertensive medication were approached and 2445 patients
completed the study (488/554 in Hong Kong Island; 738/834
in Kowloon; 1219/1312 in New Territories). The overall
response rate was 90.6%, with no significant differences among
study sites (chi-square test P¼ 0.221). The sex distribution in
nonrespondents (female, 58.8%) was similar compared with
that in participants (female, 54.2%). The major reason for
nonparticipation was that people were too busy to complete
the onsite survey in the clinic.
Data Collection
Avalid questionnaire was used for data collection, with its
face validity assessed by the same research panel. A pilot study
was conducted in 1 GOPC in October 2012 to test the reliability
of the questionnaire. The field work started from October 2012
until March 2013. The questionnaire documented patients’
information on demographics, socioeconomic characteristics,
and clinical details including long-term conditions and BPs. A
validated Chinese version of theMMAS-8 previously developed
by our research team26–28 was incorporated into the question-
naire. We followed a standard procedure of collecting BP
readings in this cross-sectional survey and BP readings on
the day of patient recruitment onsite at the clinic for all study
participants were used. All BP were measured at least 1 hour
after the subject’s last meal and at least 30minutes after
smoking or consumption of alcohol or caffeinated beverages.
Before BPmeasurement, participants were instructed to rest in a
sitting position for at least 10minutes. BP was measured by
frontline nurses using a regularly calibrated random-zero sphyg-
momanometer in the right arm, with an appropriately sized cuff
in a clinically standardized manner. The first and fifth Korotkoff
sounds were recorded as SBP and DBP, respectively. For all
study participants, BP measurements were conducted 3 times in
a sitting posture, and the mean of 3 BP readings was calculated
to determine whether BP targets were achieved. The anthropo-
metric measurements and categorization of body mass index
(BMI) levels followed a standard protocol used in our previous
studies.35,36 Body weight was measured by a regularly cali-
brated weight scale while on light clothing, and the height was
measured by a standiometer without wearing shoes.
A research nurse further referred to the electronic health
record for study subjects who self-reported the presence of
Medicine  Volume 95, Number 20, May 2016comorbid conditions in addition to hypertension to improve the
validity of patients’ reported additional conditions through
cross-check. Any discrepancies were addressed by the on-site
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.attending physician. Each interview lasted for approximately 15
to 20minutes.
Statistical Analysis
The characteristics of all patients were compared among
those having 0, 1, and 2 additional long-term conditions by
2-tailed chi-square test (for categorical variables) and indepen-
dent Student t test or analysis of variance (for continuous
variables when appropriate). Binary logistic regression
equations with backward stepwise algorithm were modeled
with medication adherence and the presence of multimorbidity
(having 1 or more long-term conditions in addition to hyper-
tension) as outcome variables, respectively. Medication adher-
ence and BP control were also tested in 2 separate logistic
regression models for their association with multimorbidity. We
examined the absence of multicollinearity to ensure the robust-
ness of all regression models. Any P values 0.05 were
considered statistically significant. All statistical analyses were
performed using IBM SPSS Statistics 20.0 (SPSS, Chicago, IL).
Ethics Review
The study was conducted with the understanding and the
written consent of each participant. The ethical approval of the
study was obtained from the Cluster Research Ethics Commit-
tee of the Hospital Authority, Hong Kong (CREC-2012.346;
KC/KE-12–0185/ER-1; UW13–016) and the Survey and Beha-
vioural Research Ethics Committee of The Chinese University
of Hong Kong. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
RESULTS
A total of 2445 subjects participated in the study, with an
average age of 65.3 years (SD 11.0). The crude prevalence of
multimorbidity was 47.4% (1159/2445), with 95% confidence
interval (CI) of 45.4% to 49.4% among all study subjects.
The proportion of hypertensive patients having 0, 1, and 2
additional long-term conditions was 52.6%, 29.1%, and 18.3%,
respectively. Slightly more than half (53.4%) of patients had
satisfactory medication adherence and 51.3% had optimal
control of both SBP and DBP simultaneously. Higher crude
proportion of multimorbidity was observed among study
participants who were older (aged 70 years and above); female
sex; having lower education level; retired or part-time
employed; having lower monthly household income; single
living without companion; longer duration and greater
categories of antihypertensive drug use (Table 1).
The crude percentage of subjects having multimorbidity
was not significantly different between hypertensive patients
with poor versus good medication adherence (48.2% [549/
1139] vs 46.7% [610/1306]; P¼ 0.735), but was significantly
higher among those who had poor SBP control (53.2% [572/
1075] vs 42.8% [587/1370]; P< 0.001) and poor DBP control
(59.9% [285/476] vs 44.4% [874/1969]; P< 0.001) (Table 1).
When compared with hypertensive patients having poor BP
control, those with satisfactory BP control had significantly
lower percentage of having coexisting long-term conditions
(22.6%, 95% CI 20.3–24.9 for patients with poor medication
adherence; and 19.8%, 95% CI 17.5–22.2 for patients with
good medication adherence) (Figure 1).
Hypertension and Multimorbidity in Primary CareFrom binary logistic regression analysis, it was found that
having multimorbidity seemed to be unlikely to achieve good
adherence in antihypertensive medicine taking, although such
www.md-journal.com | 3
TABLE 1. Characteristics of Hypertensive Patients by the Number of Coexisting Long-term Conditions
Multimorbidity (n¼ 1159) (47.4%)
All subjects

(N¼ 2445) (100%)
HT þ 0 Additional
Comorbidityy
(n¼ 1286) (52.6%)
HT þ 1 Additional
Comorbidityy
(n¼ 711) (29.1%)
HTþ 2 Additional
Comorbiditiesy
(n¼ 448) (18.3%) P
Age, yrs (SD) 65.3 (11.0) 63.3 (10.7) 66.0 (10.5) 70.1 (11.2) <0.001
Age groups
<50 158 (6.5%) 108 (68.8%) 43 (27.4%) 7 (3.8%) <0.001
50–59 634 (25.9%) 396 (62.4%) 158 (25.0%) 80 (12.6%)
60–69 792 (32.4%) 431 (54.4%) 213 (26.9%) 148 (18.7%)
70 861 (35.2%) 351 (40.8%) 297 (34.5%) 213 (24.7%)
Sex
Female 1326 (54.2%) 667 (50.3%) 398 (30.0%) 261 (19.7%) 0.032
Male 1119 (45.8%) 619 (55.4%) 313 (27.9%) 187 (16.7%)
Education
No formal education 360 (14.7%) 162 (45.0%) 119 (33.1%) 79 (21.9%) 0.003
Primary school 872 (35.7%) 449 (51.5%) 265 (30.4%) 158 (18.1%)
Junior secondary 486 (19.9%) 251 (51.6%) 138 (28.4%) 97 (20.0%)
Senior secondary or above 727 (29.7%) 424 (58.3%) 189 (26.0%) 114 (15.7%)
Employment
Part-time employed 455 (18.6%) 205 (45.0%) 121 (26.6%) 129 (28.4%) <0.001
Full-time employed 668 (27.3%) 389 (58.3%) 162 (24.3%) 117 (17.4%)
Retired 1322 (54.1%) 692 (52.3%) 428 (32.4%) 202 (15.3%)
Living status
Without companion 552 (22.5%) 267 (48.5%) 173 (31.4%) 112 (20.1%) 0.037
With companion 1893 (77.5%) 1019 (53.8%) 538 (28.4%) 336 (17.8%)
Monthly household income (HK$)
10,000 1262 (51.6%) 620 (49.1%) 385 (30.5%) 257 (20.4%) <0.001
10,001–20,000 562 (23.0%) 312 (55.5%) 145 (25.8%) 105 (18.7%)
20,001–30,000 292 (11.9%) 148 (50.7%) 99 (33.9%) 45 (15.4%)
>30,000 329 (13.5%) 206 (62.6%) 82 (24.9%) 41 (12.5%)
BMI (SD) 25.0 (4.2) 25.1 (4.3) 25.0 (4.0) 25.0 (4.1) 0.806
BMI categories
<18.5 kg/m2 68 (2.8%) 33 (48.5%) 17 (25.0%) 18 (26.5%) 0.312
18.5–22.9 kg/m2 748 (30.6%) 396 (52.9%) 207 (27.7%) 145 (19.4%)
23.0–27.4 kg/m2 1133 (46.3%) 587 (51.8%) 352 (31.1%) 194 (17.1%)
27.5 kg/m2 496 (20.3%) 270 (54.4%) 135 (27.2%) 91 (18.4%)
Family history of HT
No 1019 (41.7%) 538 (52.8%) 311 (30.5%) 170 (16.7%) 0.325
Yes 1426 (58.3%) 748 (52.5%) 400 (28.0%) 278 (19.5%)
Duration of taking anti-HT medications, yrs (categories)
<2 466 (19.1%) 275 (59.0%) 93 (20.0%) 98 (21.0%) <0.001
3–5 509 (20.8%) 258 (50.7%) 132 (25.9%) 119 (23.4%)
6–10 680 (27.8%) 354 (52.0%) 203 (29.9%) 123 (18.1%)
11–15 384 (15.7%) 202 (52.6%) 125 (32.6%) 57 (14.8%)
>15 406 (16.6%) 197 (48.5%) 158 (38.9%) 51 (12.6%)
N, anti-HT medications
1 1461 (59.8%) 781 (53.5%) 409 (28.0%) 271 (18.5%) 0.003
2 737 (30.1%) 401 (54.5%) 204 (27.6%) 132 (17.9%)
>2 247 (10.1%) 104 (42.1%) 98 (39.7%) 45 (18.2%)
Medication adherence
Poor adherence 1139 (46.6%) 590 (51.8%) 339 (29.8%) 210 (18.4%) 0.735
Good adherence 1306 (53.4%) 696 (53.3%) 372 (28.5%) 238 (18.2%)
SBP control
Poor 1075 (44.0%) 503 (46.8%) 362 (33.7%) 210 (19.5%) <0.001
Optimal 1370 (56.0%) 783 (57.2%) 349 (25.5%) 238 (17.3%)
DBP control
Poor 476 (19.5%) 191 (40.1%) 159 (33.4%) 126 (26.5%) <0.001
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Multimorbidity (n¼ 1159) (47.4%)
All subjects

(N¼ 2445) (100%)
HT þ 0 Additional
Comorbidityy
(n¼ 1286) (52.6%)
HT þ 1 Additional
Comorbidityy
(n¼ 711) (29.1%)
HTþ 2 Additional
Comorbiditiesy
(n¼ 448) (18.3%) P
Optimal 1969 (80.5%) 1095 (55.6%) 552 (28.0%) 322 (16.4%)
The monthly household income level was categorized according to the median monthly household income in Hong Kong (HK$22,400), from the
Population and Household Statistics 2013 (Census and Statistics Department, Hong Kong SAR). The BMI levels were categorized according to the
World Health Organization (WHO)-recommended cut-off points for Asian populations (2004). Poor medication adherence was defined as having
MMAS-8 score6. Poor BP control was defined as having SBP140mmHg/DBP90mmHg (or SBP130mmHg/DBP80mmHg for patients
with concomitant diabetes or chronic kidney disease). Differences between categories among subjects with no additional morbidities, 1 additional
morbidity only, and 2 additional morbidities and above were explored by chi-square test (for categorical variables) and analysis of variance (for
continuous variables).
BMI¼ body mass index, DBP¼ diastolic blood pressure, HT¼ hypertension, SBP¼ systolic blood pressure, MMAS-8¼Morisky Medication
Adherence Scale, 8 items.
Proportion across column.
Medicine  Volume 95, Number 20, May 2016 Hypertension and Multimorbidity in Primary Careinfluence was not found to be statistically significant (adjusted
odds ratio [aOR] 0.97, 95% CI 0.80–1.19, P¼ 0.802) (Table 2).
On the other hand, we found that the presence of accompanying
long-term conditions was significantly associated with poor BP
control (aOR 2.07, 95% CI 1.70–2.53, P< 0.001), whereas no
significant association was detected between poor medication
adherence level and multimorbidity (aOR 1.07, 95% CI 0.88–
1.30, P¼ 0.481). Older age (70 years), lower monthly house-
hold income level, longer duration of antihypertensive drug use,
and higher number of drug use were common contributing
factors that were significantly associated with the presence
of multimorbidity in both models, with medication adherence
and BP control as covariates, respectively (Table 3).
Hypertensive subjects with poor BP control had higher
prevalence of additional long-term conditions, particularly with
regard to diabetes mellitus (38.6%, 95% CI 35.8–41.4 vs
yProportion across row.19.7%, 95% CI 17.5–21.9), heart disease (19.2%, 95% CI
17.0–21.4 vs 11.9%, 95% CI 10.0–13.7), and nephritis and
chronic kidney disorder (14.5%, 95% CI 12.5–16.5 vs 9.1%,
0%
5%
10%
15%
20%
25%
30%
35%
Poor BP control
+ Poor adherence
Poor BP control
+ Good adherence
% Subjects with m
FIGURE 1. Proportion of subjects having multimorbidity by medical
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.95% CI 7.5–10.7) when compared with patients whose BP
levels were below the levels considered optimal. Diabetes
mellitus was the most prevalent concomitant long-term con-
dition among hypertensive patients with poor BP control
(Figure 2).
DISCUSSION
Statement of Principal Findings
From this cross-sectional study of more than 2440 Chinese
hypertensive patients, it was found that nearly half of the adult
hypertensive subjects had coexisting long-term conditions. The
presence of multimorbidity was independently associated with
advanced age, lower household income, longer duration of
antihypertensive medication use, higher number of drugs taken,
and poor BP control.We did not observe significant influence of
multimorbidity on patients’ adherence to antihypertensive
medications; whereas individuals with BP above the levels
considered optimal were significantly more likely to suffer
Optimal BP control
+ Poor adherence
Optimal BP control
+ Good adherence
ultimorbidity
adherence and blood pressure (BP) control.
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TABLE 2. Influence of Multimorbidity on Medication Adherence by Logistic Regression Analysis
Unadjusted Model Adjusted Model

OR (95% CI) P aOR (95% CI) P
Age, per 10 yrs 1.18 (1.08–1.28) <0.001 1.41 (1.02–1.96) 0.038
Sex
Female 1.00 (Ref) 1.00 (Ref)
Male 1.09 (0.93–1.28) 0.280 1.22 (1.01–1.47) 0.036
Employment
Currently employed 1.00 (Ref) 1.00 (Ref)
Retired 1.39 (1.16–1.66) <0.001 1.28 (1.02–1.61) 0.037
BP control
Poor 1.00 (Ref) 1.00 (Ref)
Optimal 1.16 (0.99–1.36) 0.072 1.19 (1.00–1.42) 0.047
Multimorbidity
No 1.00 (Ref) 1.00 (Ref)
Yes 0.88 (0.75–1.03) 0.120 0.97 (0.80–1.19) 0.802
Dependent variable: Medication adherence level (1¼ good; 0¼ poor [Morisky Medication Adherence Scale, 8 items score 6]). Independent
variables tested included age, sex, education, employment, marriage, living status, district of living, household income, body mass index, family
history, duration and number of antihypertensive drug use, BP control, and multimorbidity. Poor BP control was defined as having SBP140mmHg/
DBP 90mm Hg (or SBP 130mm Hg/DBP 80mm Hg for patients with concomitant diabetes or chronic kidney disease). Multimorbidity was
defined as the presence of one or more long-term condition in addition to hypertension.
, Re
he r
mu
Li et al Medicine  Volume 95, Number 20, May 2016aOR¼ adjusted odds ratio, CI¼ confidence interval, OR¼ odds ratio
Only variables that were statistically significant (P values <0.05) in t
covariates in the final regression model to test the association betweenfrom coexisting long-term conditions such as diabetes, heart
disease, or chronic kidney disorder.
Relationship With Literature and Explanation of
Findings
Patients with multiple long-term conditions are very fre-
quently encountered in routine clinical practice particularly
among those with hypertension. Previous investigations on the
determinants ofmedication adherence andBP control in the same
Hong Kong primary care population suggested the necessity for
further research from a multimorbidity perspective.37 National
data collected in Scotland, UK, showed that 78% of hypertensive
patients seen in general practice had at least 1 other long-term
conditions from a list of 40 chronic conditions.10 There have also
been heterogeneousmethods used across observational studies to
define multimorbidity among different study populations. An
earlier systematic review38 showed that the proportion of multi-
morbidity increased as age advanced, and its prevalence in older
persons ranged from 55% to 98%, suggesting considerable dis-
ease complexity and enormous burden on health care. In our
study, the crude proportion ofmultimorbiditywas lower than that
reported in the United Kingdom, which may be due (at least in
part) to the differences in the number of chronic diseases con-
sidered and the data collection approach used. We found that the
household income level was an independent factor associated
withmultimorbidity,meaning that hypertensive subjects living in
deprived householdweremore likely to confrontmultiple comor-
bid conditions. The findings are compatible with previous studies
in the western countries, reporting that with higher degrees
of deprivation, the mix of multiple medical problems
become greater,9,10 or what has been recognized as the ‘‘inverse
care law.’’39
There is a large volume of epidemiological evidence that
consistent BP control is linked with improved cardiovascular
6 | www.md-journal.comoutcome.40 The Danish General Practice Database study pre-
viously evaluated the association between multimorbidity and
rate of BP control in a large cohort of hypertensive patients
which showed that the BP control rates differed substantially
between patients with comorbidities.32 In particular, only
16.5% of hypertensive patients with diabetes in Danish general
practice had BP below 130/80mm Hg, which was a recom-
mended therapeutic target for individuals with diabetes melli-
tus.15,21–24 In our study where the same BP cut-off value was
used, the findings that the prevalence of diabetes was the highest
among individuals with poor BP control were complementary to
earlier observations in Denmark. Another study conducted by
the British Hypertension Society pointed out that the BP of
<130/80mm Hg as a rigorous target in patients with diabetes
may be more difficult to reach than BP targets of <140/90mm
Hg.41 Further research might need to identify the ideal BP level
at which maximum protection against diabetic complications is
conferred, and below which the reduction no longer delivers a
benefit that exceeds risk42 for the diabetes population of differ-
ent age groups, particularly for the Asian population. Another
explanation could be that some physicians may consider 140/
90mmHg as ‘‘close enough to target,’’ and with clinical inertia,
physicians prefer to only deal with the most pressing or
symptomatic problem alone while observing if the BP level
is not very high. It is also possible that the perceptions of
physicians towards optimal BP control may be different
between patients with or without multimorbidities.43 In contrast
to the methodology used in a more recent UK study in which
multiple SBP measures collected from the Lambeth DataNet
were analyzed as continuous variables,44 it is worth noting that
our study sought to identify success or failure in achieving the
BP target. The perspective on BP control provides real-world
f¼ reference.
egression equation using backward stepwise algorithm were included as
ltimorbidity and medication adherence.clinical insights as lowering BP to particular target values often
represents a more difficult issue. Although there is a need to
exercise some caution in the interpretation as we were unable to
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Factors Association With the Presence of Multimorbidity Among Hypertensive Patients
Unadjusted Model Adjusted Model 1

Adjusted Model 2y
OR (95% CI) P aOR (95% CI) P aOR (95% CI) P
Age, yrs
<50 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
50–59 1.32 (0.91–1.91) 0.146 1.06 (0.68–1.65) 0.809 1.10 (0.70–1.71) 0.688
60–69 1.82 (1.27–2.62) 0.001 1.41 (0.91–2.19) 0.125 1.48 (0.95–2.31) 0.082
70 3.17 (2.20–4.55) <0.001 2.39 (1.52–3.76) <0.001 2.37 (1.50–3.74) <0.001
Monthly household income (HK$)
>30,000 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
20,001–30,000 1.65 (1.19–2.27) 0.002 1.06 (0.77–1.46) 0.708 1.11 (0.81–1.53) 0.521
10,001–20,000 1.36 (1.03–1.79) 0.031 1.05 (0.75–1.47) 0.773 1.11 (0.79–1.57) 0.544
10,000 1.76 (1.37–2.26) <0.001 1.52 (1.04–2.22) 0.030 1.54 (1.05–2.26) 0.027
Use of antihypertensive drugs
Duration, per yr 1.01 (1.00–1.02) 0.053 1.02 (1.01–1.04) <0.001 1.02 (1.01–1.04) 0.001
N, anti-HT medications
1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
2 0.96 (0.80–1.15) 0.648 0.87 (0.70–1.09) 0.227 0.85 (0.68–1.06) 0.160
>2 1.57 (1.20–2.06) 0.001 1.52 (1.10–2.10) 0.012 1.58 (1.14–2.20) 0.006
Medication adherence
Good (MMAS >6) 1.00 (Ref) 1.00 (Ref) –
Poor (MMAS 6) 1.06 (0.91–1.25) 0.449 1.07 (0.88–1.30) 0.481 – –
BP control
Optimal BP control 1.00 (Ref) – 1.00 (Ref)
Poor BP control 1.60 (1.37–1.88) <0.001 – – 2.07 (1.70–2.53) <0.001
Dependent variable: presence of multimorbidity (1¼ yes; 0¼ no). Independent variables tested included age, sex, education, employment,
marriage, living status, district, household income, body mass index, family history, medication adherence, duration and number of antihypertensive
drug use, and BP control.
aOR¼ adjusted odds ratio, CI¼ confidence interval, MMAS¼Morisky Medication Adherence Scale (8 items), OR¼ odds ratio, Ref¼ reference.
Only variables that were statistically significant (P values<0.05) in the regression equation using backward stepwise algorithm were included as
covariates in the final regression model to test the association between medication adherence and multimorbidity.
yOnly variables that were statistically significant (P values< 0.05) in the regression equation using backward stepwise algorithm were included as
covariates in the final regression model to test the association between blood pressure control and multimorbidity.
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FIGURE 2. Prevalence of major coexisting long-term conditions among participants by blood pressure (BP) control.
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comprehensively retrieve from the entire subjects a whole
spectrum covering all previous BP measurements in past visits,
the evidence from our findings suggests that the focus on
achieving good BP control in the Chinese population should
not be neglected.
Previous literature has suggested that patient nonadherence
to prescribed antihypertensive therapy could serve as a major
obstacle to achieving good clinical outcomes.45 In our study,
however, we did not detect a significant association between
medication adherence and the presence of multimorbidity. It
might be that having accompanying chronic conditions requires
higher intensity and complexity of treatment regime such that
polypharmacy and multiple daily dosing may reduce the drug
adherence.45,46 One may argue otherwise that the presence of
multimorbidity may be linked with increased adherence to the
medication because of the perceived seriousness of multiple
conditions47; despite that, we did not collect such information.
Nevertheless, it seems likely that hypertensive subjects were
prone to have poor adherence to medications in the presence of
concomitant long-term conditions based on our study findings,
albeit such association was not statistically significant. We
therefore speculated that the association might be mediated
by factors such as prescription pattern, treatment intensification,
or health behaviors,48 which needs further in-depth causal
investigation. The US National Health and Nutrition Examin-
ation Study depicted a picture of unsatisfactory BP control,
despite the awareness of hypertension among people who were
more likely to be taking antihypertensive medications.49 Our
results that coexisting diabetes, heart disease, or chronic kidney
disorder was more prevalent in people with poor BP control also
echoed earlier US studies in which adults with diabetes had the
greatest population burden of uncontrolled BP, followed by
adults with chronic kidney disease and cardiovascular disease.49
A study in Australia showed that multimorbidity could lead to
difficulties in pharmaceutical care management in primary
care.50 Given that most medication treatments are delivered
according to single-disease-oriented guidelines,51 the explora-
tion of appropriateness of medication prescriptions among
multimorbid hypertensive patients is warranted.
Strengths and Limitations of the Study
This study adopted a multistage sampling design to recruit
hypertensive patients in the public primary care setting of Hong
Kong. Multimorbidity was assessed using a well-recognised
methodology supplemented by physician documentations.
Medication adherence was evaluated by a validated tool, and
BP was examined in a standardized approach. However, a
number of limitations should be addressed. Firstly, it should
be noted that we only included 1 GOPC in each geographic
region, which could limit the generalizability of our findings to
the entire population of Hong Kong. Secondly, the cross-sec-
tional design could only evaluate association, instead of cause-
and-effect relationships. Thirdly, a patient self-report survey
restricted the inclusion of questions on physician-prescribing
patterns that might differ among physicians and regions, and the
discrimination between essential and secondary hypertension
was not accounted for in this study. In addition, recall bias might
exist in using MMAS-8 as a self-report measure, and the
Hawthorne effect may also bias patients’ answers in reporting
their adherence to antihypertensive medications. Last but not
Li et althe least, subjects’ ambulatory or home BP readings in out-of-
clinic settings52 were not monitored in our study, and thus the
determination of optimal BP control was based on clinic-based
8 | www.md-journal.commeasurement alone instead of an average over a period of time.
One may argue that people with ’masked hypertension’ would
be misclassified, albeit this phenomenon was seen much more
frequently in younger patients. Given that those under 50 years
of age only accounted for a very small proportion (6.5%), the
effects of possible misclassification of ’masked hypertension’
on the study results were therefore considered minimum.
Conclusions and Future Prospects
This study indicated that hypertensive patients presented
with poor BP control should be evaluated in a more meticulous
manner for the possible presence of other coexisting medical
conditions, in particular, diabetes. On the other hand, hyper-
tensive patients with multimorbidity should have their BP
monitored more closely as they tended to have poorer BP
control. This has important implications for both policy makers
and physicians, because the high prevalence of multimorbidity
points towards the need to prioritize more healthcare resources
to address the multiple medical conditions among hypertensive
patients. It was well-recognised that earlier detection of shared
risk factors could lead to better clinical outcomes by reducing
long-term complications.53 From a healthcare system’s point of
view, health services delivery should be reviewed and oriented
to address the rising challenges of multimorbidity.54,55 These
include combined efforts to enhance continuity of care, coordi-
nation among different healthcare professionals, and the pro-
mulgation of adopting holistic care models. The findings also
call for more prospective studies to evaluate the effect of
multidrug prescribing patterns on multimorbidity, and the best
primary care-based interventional strategies to handle the com-
plexity of hypertension management which demands urgent
attention.
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